急性髓系白血病(acute myeloid leukemia,AML)是一种以髓系原始细胞异常克隆性增殖为特征,导致异常的原始细胞在骨髓内积聚,抑制骨髓正常造血功能的恶性血液病。大部分AML患者经诱导化疗后能够达到完全缓解(complete remission,CR),随后给予巩固化疗及维持治疗,但复发率依然很高。因此延长患者的缓解期,尤其是对不适合异基因造血干细胞移植的患者,免疫治疗日 Acute myeloid leukemia (AML) is a type of hematologic malignancy characterized by aberrant clonal proliferation of myeloid blasts, resulting in the accumulation of abnormal primary cells in the bone marrow and inhibiting the normal hematopoietic function of the bone marrow. Most AML patients achieve complete remission (CR) after induction chemotherapy, followed by consolidation chemotherapy and maintenance therapy, but the recurrence rate is still high. Thus prolonging the remission of patients, especially for patients not suitable for allogeneic hematopoietic stem cell transplantation, immunotherapy days